Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

The drugmaker has already taken legal action against some businesses selling compounded semaglutide in a way that does not comply with the FDA's regulations. The price of GLP-1 drugs has attracted ...

Current GLP-1-based obesity medications are effective in achieving ... At 2024 ObesityWeek, Hanmi highlighted HM15275’s mechanism of action, which facilitates favorable metabolic phenotype change and ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Cambridge UK biopharma company Apollo Therapeutics could pay around $1 billion to Chinese company Sunshine Lake Pharma to ...

SINGAPORE’S authorities are reviewing advertisements that telemedicine providers have put up for certain weight-loss drugs, ...

In announcing RFK Jr. as having a significant role in healthcare in his administration, he has targeted healthcare in America ...